| Ambetter Health Texas Wellcare Allwell Medicare Clinical | Overactive Bladder Agents | 2025-06-01 |
| UHC Commercial Medical & Drug | Adakveo® (Crizanlizumab-Tmca) – Commercial Medical Benefit Drug Policy | 2025-06-01 |
| UHC Commercial Medical & Drug | Intravenous Enzyme Replacement Therapy (ERT) for Gaucher Disease – Commercial Medical Benefit Drug Policy | 2025-06-01 |
| UHC Commercial Medical & Drug | Qalsody® (Tofersen) – Commercial Medical Benefit Drug Policy | 2025-06-01 |
| UHC Commercial Medical & Drug | RNA-Targeted Therapies (Amvuttra® and Onpattro®) – Commercial Medical Benefit Drug Policy | 2025-06-01 |
| UHC Commercial Medical & Drug | Trogarzo® (Ibalizumab-Uiyk) – Commercial Medical Benefit Drug Policy | 2025-06-01 |
| UHC Commercial Medical & Drug | Veopoz® (Pozelimab-Bbfg) – Commercial Medical Benefit Drug Policy | 2025-06-01 |
| Meridian Illinois Medicaid Clinical | Bone-Anchored Hearing Aid | 2025-06-01 |
| Meridian Illinois Medicaid Clinical | Chiropractic Care | 2025-06-01 |
| Meridian Illinois Medicaid Clinical | Hospice Services | 2025-06-01 |